Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE -141.3%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $15M | $7M | $6M | $4M | $19M | $129M | — | — |
| Enterprise Value | $15M | $6M | $5M | $8M | $4M | $104M | — | — |
| P/E Ratio → | -1.29 | — | — | — | — | — | — | — |
| P/S Ratio | 0.36 | 0.16 | 0.16 | 0.13 | 0.68 | 5.34 | — | — |
| P/B Ratio | 1.29 | 0.63 | 1.36 | 0.89 | 0.81 | 11.34 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.15 | 0.13 | 0.24 | 0.12 | 4.32 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.7% | 78.7% | 50.1% | 48.8% | 47.0% | 47.1% | 51.9% | 52.6% |
| Operating Margin | -21.9% | -21.9% | -46.1% | -66.6% | -64.8% | -104.6% | -51.0% | -57.0% |
| Net Profit Margin | -25.3% | -25.3% | -47.6% | -59.1% | -2.2% | -156.5% | -58.3% | -41.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -141.3% | -141.3% | -385.0% | -140.4% | -3.6% | -439.4% | -188.5% | — |
| ROA | -41.6% | -41.6% | -71.0% | -51.1% | -1.2% | -97.5% | -41.5% | -38.2% |
| ROIC | -100.2% | -100.2% | -209.9% | -201.7% | -173.8% | — | — | -1556.5% |
| ROCE | -68.4% | -68.4% | -172.8% | -113.9% | -53.6% | -85.3% | -52.3% | -87.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.59 | 1.11 | 1.13 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.02 | -0.22 | 0.85 | -0.66 | -2.16 | -1.39 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -20.24 | -20.24 | -7.42 | -32.53 | -0.64 | -103.60 | -2.77 | -4.07 |
Net cash position: cash ($6M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.52 | 1.52 | 1.72 | 1.28 | 2.06 | 3.36 | 4.43 | 2.00 |
| Quick Ratio | 1.40 | 1.40 | 1.17 | 0.67 | 1.72 | 3.03 | 2.82 | 1.11 |
| Cash Ratio | 0.54 | 0.54 | 0.49 | 0.08 | 1.33 | 1.77 | 1.83 | 0.62 |
| Asset Turnover | — | 1.46 | 1.69 | 1.22 | 0.56 | 0.45 | 0.78 | 0.91 |
| Inventory Turnover | 6.24 | 6.24 | 2.80 | 1.60 | 2.12 | 2.86 | 1.28 | 1.18 |
| Days Sales Outstanding | — | 63.81 | 52.01 | 55.30 | 94.27 | 57.31 | 63.69 | 66.72 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $12M | $6M | $2M | $1M | $855237 | $580000 | $607000 |
Liquidity and financing risk
Based on current market data, BFRI trades at a P/S multiple of 0.30, which, according to recent financial filings, reflects a market valuation heavily discounted for the company's inability to demonstrate consistent, profitable growth relative to its specialty dermatology peers like Journey Medical Corporation.
The low P/S ratio suggests that investors are pricing the company as a distressed asset rather than a growth-stage pharmaceutical firm. This valuation implies significant skepticism regarding the company's ability to scale its drug-device combination model without further dilutive capital raises.
As reported in quarterly financial statements, BFRI maintains a robust gross margin of 81.8% as of 2026Q1, yet this figure is undermined by an operating margin of -42.8%, indicating that the firm's core earning power is currently insufficient to cover its commercialization infrastructure.
While the high gross margin confirms the inherent value of the Ameluz product, the persistent operating deficit suggests that the company's fixed-cost structure is too heavy for its current revenue base. Investors should monitor whether the company can achieve operating leverage before its cash reserves are fully depleted.
According to historical data, the company's cash conversion cycle has fluctuated wildly, reaching -138 days in 2026Q1, which, based on reported figures, suggests that management is struggling to maintain a stable relationship between inventory turnover and the collection of accounts receivable.
The extreme volatility in the CCC indicates that working capital management is currently reactive rather than strategic. This inconsistency complicates the forecasting of cash flows and suggests that the company may be experiencing uneven demand patterns or supply chain friction in its hardware distribution.
Based on the provided balance sheet, the debt-to-equity ratio of 1.27 in 2026Q1, combined with a negative interest coverage ratio of -34.56, indicates that the company's ability to service its debt obligations is highly precarious compared to more stable industry participants.
The erratic nature of the debt-to-equity ratio over the last ten quarters suggests that the company has relied on inconsistent financing methods to stay afloat. This leverage profile warrants further investigation into the terms of existing debt and the potential for future covenant breaches.
The P/E ratio is frequently misapplied to BFRI, as the company's negative earnings and high-burn commercialization phase render traditional valuation metrics obsolete, obscuring the true value of the installed RhodoLED lamp base which serves as the primary driver for future recurring revenue.
Investors should instead focus on metrics like 'revenue per installed lamp' or 'customer acquisition cost' to gauge the health of the business model. Relying on P/E ratios in this context ignores the platform-like nature of the drug-device combination and misrepresents the company's long-term potential.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BFRI stock.
Biofrontera Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
Biofrontera Inc.'s return on equity (ROE) is -141.3%. The historical average is -216.4%.
Based on historical data, Biofrontera Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Biofrontera Inc. has 78.7% gross margin and -21.9% operating margin.